TABLE 2.
Antimicrobial activity of telavancin and comparator agents tested against a contemporary (2011 to 2013) U.S. collection of clinical isolates using a recently approved and revised susceptibility testing method
| Organism categorya (no. tested) and antimicrobial agent | MIC (μg/ml) |
% susceptible/% intermediate/% resistantb |
|||
|---|---|---|---|---|---|
| 50% | 90% | FDA | CLSI | EUCAST | |
| MSSA (4,959) | |||||
| Telavancin | 0.03 | 0.06 | 100.0/-c/- | -/-/- | -/-/- |
| Vancomycin | 1 | 1 | 100.0/0.0/0.0 | 100.0/0.0/0.0 | |
| Daptomycin | 0.25 | 0.5 | >99.9/-/- | >99.9/0.0/<0.1 | |
| Linezolid | 1 | 1 | >99.9/0.0/<0.1 | >99.9/0.0/<0.1 | |
| Levofloxacin | 0.25 | 4 | 88.8/0.9/10.3 | 88.8/0.9/10.3 | |
| Erythromycin | 0.25 | >16 | 65.6/3.7/30.7 | 66.0/1.3/32.7 | |
| Clindamycin | ≤0.25 | ≤0.25 | 95.2/0.1/4.7 | 94.8/0.4/4.8 | |
| Gentamicin | ≤1 | ≤1 | 99.2/0.2/0.6 | 99.0/0.0/1.0 | |
| Tetracycline | ≤0.25 | ≤0.25 | 96.2/0.7/3.1 | 95.3/0.2/4.5 | |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | 99.5/0.0/0.5 | 99.5/0.1/0.4 | |
| MRSA (4,651) | |||||
| Telavancin | 0.03 | 0.06 | 100.0/-/- | -/-/- | 100.0/-/- |
| Vancomycin | 1 | 1 | >99.9/<0.1/0.0 | >99.9/0.0/<0.1 | |
| Daptomycin | 0.25 | 0.5 | >99.9/-/- | >99.9/0.0/<0.1 | |
| Linezolid | 1 | 1 | 99.9/0.0/0.1 | 99.9/0.0/0.1 | |
| Levofloxacin | 4 | >4 | 31.3/2.2/66.5 | 31.3/2.2/66.5 | |
| Erythromycin | >16 | >16 | 10.4/1.9/87.7 | 10.6/0.5/88.9 | |
| Clindamycin | ≤0.25 | >2 | 70.5/0.1/29.4 | 70.2/0.3/29.5 | |
| Gentamicin | ≤1 | ≤1 | 96.8/0.1/3.1 | 96.5/0.0/3.5 | |
| Tetracycline | ≤0.25 | 1 | 94.9/0.4/4.7 | 92.6/2.0/5.4 | |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | 97.8/0.0/2.2 | 97.8/0.2/2.0 | |
| MRSA with vancomycin MIC 2–4 μg/ml (4,651) | |||||
| Telavancin | 0.06 | 0.06 | 100.0/-/- | -/-/- | 100.0/-/- |
| Vancomycin | 2 | 2 | 98.9/1.1/0.0 | 98.9/0.0/1.1 | |
| Daptomycin | 0.5 | 1 | 97.8/-/- | 97.8/0.0/2.2 | |
| Linezolid | 1 | 2 | 98.9/0.0/1.1 | 98.9/0.0/1.1 | |
| Levofloxacin | >4 | >4 | 14.4/0.0/85.6 | 14.4/0.0/85.6 | |
| Erythromycin | >16 | >16 | 5.6/1.1/93.3 | 5.6/1.1/93.3 | |
| Clindamycin | >2 | >2 | 36.7/0.0/63.3 | 36.7/0.0/63.3 | |
| Gentamicin | ≤1 | 2 | 91.1/0.0/8.9 | 88.9/0.0/11.1 | |
| Tetracycline | ≤0.25 | 2 | 95.6/1.1/3.3 | 88.9/6.7/4.4 | |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | 97.8/0.0/2.2 | 97.8/1.1/1.1 | |
| MDR MRSA (1,371) | |||||
| Telavancin | 0.03 | 0.06 | 100.0/-/- | -/-/- | 100.0/-/- |
| Vancomycin | 1 | 1 | 99.9/0.1/0.0 | 99.9/0.0/0.1 | |
| Daptomycin | 0.25 | 0.5 | 99.9/-/- | 99.9/0.0/0.1 | |
| Linezolid | 1 | 1 | 99.7/0.0/0.3 | 99.7/0.0/0.3 | |
| Levofloxacin | >4 | >4 | 0.9/0.3/98.8 | 0.9/0.3/98.8 | |
| Erythromycin | >16 | >16 | 0.5/0.4/99.1 | 0.5/0.1/99.4 | |
| Clindamycin | >2 | >2 | 6.3/0.0/93.7 | 6.3/0.0/93.7 | |
| Gentamicin | ≤1 | 4 | 90.2/0.2/9.6 | 89.9/0.0/10.1 | |
| Tetracycline | ≤0.25 | >8 | 88.6/0.2/11.2 | 82.4/6.1/11.5 | |
| Trimethoprim-sulfamethoxazole | ≤0.5 | ≤0.5 | 93.9/0.0/6.1 | 93.9/0.7/5.4 | |
a
MSSA, methicillin-susceptible S. aureus; MRSA, methicillin-resistant S. aureus; MDR, multidrug resistant.
b
Telavancin breakpoint criteria for S. aureus according to the labeling supplement for the product (Vibativ) and EUCAST (MRSA only) at ≤0.12 μg/ml for susceptibility.
c
-, breakpoint not available.